Pharmaceutical consultations in oncology: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique – SFPO) guidelines

Petit-Jean, Emilie; Correard, Florian; Maillan, G.; Crozals, F. De; Bertrand, B; Regnier, V.; Chevrier, R.; Streicher, Caroline; Madelaine, Isabelle; Pourroy, Bertrand

doi:10.1097/op9.0000000000000011

Cited by 7 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prompt implementation of clinical pharmacy in COVID-19+ units contributes to treatment optimization in the face of a theoretical risk of drug-related iatrogenesis in this novel population -risk also run by cancer patients in the COVID-19 context. The benefit of pharmaceutical expertise in cancer is well-established [110][111][112], and the pandemic has led to adaptation of oncology clinical pharmacy activity: an organizational approach to limit contact-time in the care units (pharmaceutical care including consultations, medication reconciliation) and a pharmacologic approach (medication prescription analysis). Neither approach needs to be short-term with a return to business-as-usual envisaged within a matter of weeks: medium and even long-term perspectives are possible.…”

Section: Guidelines For the Practice Of Oncology Clinical Pharmacy Under The Covid-19 Pandemicmentioning

confidence: 99%

Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines)

Slimano

Baudouin

Zerbit

et al. 2020

Cancer Treatment Reviews

Self Cite

View full text Add to dashboard Cite

The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care.This review is dedicated to the optimization of care pathways and therapeutics in cancer patients during the pandemic and aims to discuss successive issues.First we focused on the international guidelines proposing adjustments and alternative options to cancer care in order to limit hospital admission and cytopenic treatment in cancer patients, most of whom are immunocompromised.In addition cancer patients are prone to polypharmacy, enhancing the risk of drug-related problems as adverse events and drug-drug interactions. Due to increased risk in case of COVID-19, we reported a comprehensive review of all the drug-related problems between COVID-19 and antineoplastics.Moreover, in the absence of approved drug against COVID-19, infected patients may be included in clinical trials evaluating new drugs with a lack of knowledge, particularly in cancer patients. Focusing on the several

show abstract

Section: Guidelines For the Practice Of Oncology Clinical Pharmacy Under The Covid-19 Pandemicmentioning

confidence: 99%

Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines)

Slimano

Baudouin

Zerbit

et al. 2020

Cancer Treatment Reviews

Self Cite

View full text Add to dashboard Cite

show abstract

“…12: Oncologic clinical pharmacy activities are maintained. 40,42,43,53 These activities make it possible to optimize the therapeutic care of the patient with cancer.…”

Section: Guidelinesmentioning

confidence: 99%

“…[40][41][42][43] Pharmaceutical consultations contribute to the optimal management of the patient with cancer. 53 Reducing contact with at-risk patients, such as patients with cancer, requires telephone consultations or teleconsultations. 2,20,26,28 Increased attention will be paid to the initiation of treatment.…”

Section: Guidelinesmentioning

confidence: 99%

See 1 more Smart Citation

Providing Oncology Pharmacy Services During the Coronavirus Pandemic: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique [SFPO]) Guidelines

Pourroy

Tournamille

Bardin

et al. 2020

JCO Oncology Practice

Self Cite

View full text Add to dashboard Cite

PURPOSE: Patients with cancer are at higher risk for contracting the COVID-19 infection and are more likely to have higher morbidity and mortality. This is a big challenge for oncology teams that have to treat patients to avoid contamination by SARS-CoV-2. The aim of the current work is to present oncology pharmacy practice guidelines during the COVID-19 pandemic to secure the pharmaceutical care of patients with cancer. METHODS: The bureau of the French Society for Oncology Pharmacy proposed these recommendations according to the French High Authority of Health following the Guidelines of Good Practice, slightly modified according to the pandemic crisis situation. These guidelines were developed by a working group of 7 experts in oncology pharmacy practice. Furthermore, the guidelines were assessed by 31 independent reviewers. RESULTS: One hundred percent of reviewers approved the guidelines and 90% of them suggested some improvements. The final version incorporates the best comments and consists of 26 recommendations organized in 8 different sections. CONCLUSION: These guidelines allow secure pharmaceutical management of patients with cancer during the COVID-19 pandemic.

show abstract

“…21 The French Society of Oncology Pharmacy (Société Française de Pharmacie Oncologique) recommends the involvement of an oncology pharmacist in this type of follow-up and especially in the management of OATs. 22 Several studies 23 have shown a positive effect on treatment adherence among patients receiving a pharmaceutical consultation as part of a multidisciplinary consultation program (MCP). The program's main objective to increase treatment safety and efficacy 24 by educating the patient and providing drug information.…”

Section: Introductionmentioning

confidence: 99%

Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer

Féral

Boone

Lucas

et al. 2021

J Oncol Pharm Pract

View full text Add to dashboard Cite

Purpose To evaluate adherence (as measured by the medication possession ratio) to the first ever course of oral antineoplasic treatment in cancer patients before and after the implementation of a multidisciplinary consultation program (involving an oncologist, a pharmacist, and a nurse) and to investigate the program's impact on adverse events and drug-related problems. Patients and Methods In a retrospective single-center study, we compared the medication possession ratio 2 months after treatment initiation in a control group (before multidisciplinary consultation program implementation) versus an interventional group (after multidisciplinary consultation program implementation). Results Two months after oral antineoplasic treatment initiation, the mean ± standard deviation medication possession ratio did not differ significantly when comparing the interventional (multidisciplinary consultation program) group ( n = 33; 0.99 ± 0.06) with the control group ( n = 64; 0.94 ± 0.16) ( p = 0.062). Patients in the multidisciplinary consultation program group had fewer adverse events in general (41, vs 109 in the control group; p = 0.048) and digestive adverse events in particular (6 vs 29, respectively; p = 0.007). A total of 53 and 40 drug-related problems were identified in the control and multidisciplinary consultation program groups, respectively ( p = 0.074). Conclusions Implementation of an multidisciplinary consultation program was not associated with a significant difference in drug adherence (as assessed by the medication possession ratio), which was good before and after implementation. The multidisciplinary consultation program was associated with a lower incidence of adverse events.

show abstract

Pharmaceutical consultations in oncology: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique – SFPO) guidelines

Cited by 7 publications

References 16 publications

Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines)

Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines)

Providing Oncology Pharmacy Services During the Coronavirus Pandemic: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique [SFPO]) Guidelines

Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer

Contact Info

Product

Resources

About